Hot Investor Mandate: Venture Philanthropy Investor Deploys $1-2M in Seed and Series A Cardiovascular and Metabolic Technologies Globally

The firm is a U.S.-based philanthropic venture investor focused on accelerating the development of technologies for the diagnosis and treatment of cardiovascular and neurovascular diseases. The firm typically invests $1M–$2M per company and seeks to make approximately four to five new investments annually. The firm targets Seed and Series A companies and operates through an evergreen investment structure, supporting technologies that can achieve meaningful development milestones and attract subsequent institutional financing. The firm invests globally.

The firm invests across biotechnology, medical technology, diagnostics, and regenerative medicine, with a particular emphasis on cardiovascular, neurovascular, and metabolic diseases. Areas of interest include diabetes, dyslipidemia, obesity, and technologies addressing significant unmet clinical needs. The firm is broadly opportunistic regarding specific technologies and seeks innovations capable of improving patient outcomes and advancing treatment options. The firm prioritizes opportunities where investment capital can help companies achieve critical value-inflection milestones necessary for larger financing rounds.

From a company and management team perspective, the firm seeks technologies with clear potential to improve patient therapy and meaningful intellectual property protection. The firm places particular emphasis on a well-defined use of proceeds, achievable development milestones, and a clear understanding of the next financing round, including its anticipated size and potential sources. The firm favors companies capable of demonstrating measurable progress toward clinical and commercial development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Leave a Reply